CORTLANDT MANOR, N.Y., May 16, 2016 /PRNewswire/ -- Polymedco is proud to announce the launch of Epi proColon®, a newly FDA approved blood test for colorectal cancer screening in patients that are non-compliant for stool testing or colonoscopy. This is the first approved molecular DNA blood test for colorectal cancer screening.
Approximately 25-30 million people remain unscreened in the US and this test will be marketed towards the population that is non-compliant with screening and is unwilling or unable to complete both FIT stool testing and colonoscopy.
Epi proColon detects cell-free tumor DNA circulating in blood. The proprietary Septin 9 gene methylation biomarker is extracted from plasma by enhanced sensitive nucleic acid isolation, undergoes bisulfite conversion, real-time PCR and analysis. The test can be performed in any high complexity clinical laboratory.
This test complements Polymedco's colorectal cancer screening product offering. Polymedco is the leader in FIT testing, with the first FDA cleared automated FIT analyzer, OC-Auto® and the high throughput FIT analyzer OC-Auto® Sensor Diana, and the recently cleared OC-Light® S FIT manual point of care test.
About Polymedco: Since 1980, Polymedco has evolved into a leading manufacturer, marketer, and distributor in the clinical laboratory marketplace. Polymedco supplies clinical diagnostic test kits that are specialized in hematology and cancer screening. We are a world leader in non-invasive colorectal cancer screening technology, providing the new standard of care with the OC-Auto® and OC-Light® product lines.
Polymedco Cancer Diagnostic Products, LLC.
510 Furnace Dock Road
Cortlandt Manor, NY 10567 USA
OC-Auto and OC-Light are Registered Trademarks of Polymedco CDP, LLC.
Epi proColon is a Registered Trademark of Epigenomics, AG
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/polymedco-announces-the-launch-of-epi-procolon-in-the-united-states-300269206.html